Home page > Publications > MGHI papers
MGHI papers
SFCE-METRO01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor
The SFCE group has just published in Pediatric Blood and Cancer the second part of their metronomic phase II trial entitled SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumors. This trial is based on a pilot study initialy published in Oncotarget. Treatment consisted of an eight-week cycle of : oral celecoxib (...)
Successfully targeting the cancer system with metronomics for medulloblastoma
The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term (...)
Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory ATRT
Mahe Berland, Laetitia Padovani, Angélique Rome, Grégoire Pech-Gourg, Dominique Figarella-Branger and Nicolas André from the children hospital of La Timone and the Centre de Recherche en Oncologie Biologique et en Oncopharmacologie, INSERM-UMR 79 911, Aix-Marseille University, France have just published a case reported entitled : Sustained Complete (...)
Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents
E Yee, E Pasquier, G Iskander, K Wood D Stc Black and N Kumar from the a School of Chemistry, the Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of NSW, Randwick, and the Metronomics Global Health Initiative have just reported in Bioorganic & Medicinal Chemistry an article entitled : Synthesis (...)
Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma
Shripad Banavali from the Department of Medical and Pediatric Oncology, Tata Memorial Centre, in India; Eddy Pasquier from the Aix Marseille Université, Inserm, CRO2 UMR_S 91, Marseille France and Nicolas André from the Service d’Hématologie & Oncologie Pédiatrique, AP-HM in Marseille France and all members of MGHI have just published a case report (...)
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.
A joint work of researcher from the Children’s Cancer Institute Australia, the Centre de Recherche en Oncologie biologique et Oncopharmacologie, Aix-Marseille University the Department of Hematology and Pediatric Oncology, La Timone University Hospital of Marseille and MGHI entitled β-blockers increase response to chemotherapy via direct antitumour and (...)
‘Hard’ Drug Repurposing for Precision Oncology: the Missing Link?
As part of a "research topic" on drug repositioning and metronomic chemotherapy, opened for submission in Fontiers in Pharmacology, Pan Pantziarka, Gauthier Bouche and Nicolas André from the Anticancer Fund, Belgium , The George Pantziarka TP53 Trust, United Kingdom, the Department of Pediatric Hematology-Oncology, Assistance Publique Hôpitaux de (...)
